PCI Biotech file patents for combination of siRNA and the PCI technology
Photocure's daughter company PCI Biotech is developing a proprietary technology for site-specific drug delivery and drug enhancement called Photochemical Internalisation (PCI). PCI Biotech has, according to an agreement with Rikshospitalet-Radiumhospitalet HF, filed two patent applications covering the combination of siRNA (short interfering RNA) and the PCI technology. PCI Biotech plans to explore this field of the PCI-technology and will sponsor a dedicated research position within this field the next three years.
Kjetil Hestdal, President and CEO of Photocure, says: "Achieving safe and efficient gene delivery in the body has been a major limiting factor in the development of gene therapy. Our goal is to develop an effective treatment of cancer therapy through the combination of siRNA and the PCI technology."
Most read news
Other news from the department research and development

Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

INTEGRA Biosciences acquires start-up Miroculus to accelerate genomics

Researchers develop a detector for continuously monitoring toxic gases - The material could be made as a thin coating to analyze air quality in industrial or home settings over time
